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Abstract. 
 
The p53 oncosuppressor protein regulates
cell cycle checkpoints and apoptosis, but increasing evi-
dence also indicates its involvement in differentiation
and development. We had previously demonstrated
that in the presence of differentiation-promoting stim-
uli, p53-defective myoblasts exit from the cell cycle but
do not differentiate into myocytes and myotubes. To
 
identify the pathways through which p53 contributes
to skeletal muscle differentiation, we have analyzed
the expression of a series of genes regulated during
myogenesis in parental and dominant–negative p53
(dnp53)-expressing C2C12 myoblasts. We found that in
 
dnp53-expressing C2C12 cells, as well as in p53
 
2
 
/
 
2
 
 pri-
mary myoblasts, pRb is hypophosphorylated and prolif-
eration stops. However, these cells do not upregulate
pRb and have reduced MyoD activity. The transduction
of exogenous 
 
TP53
 
 or 
 
Rb
 
 genes in p53-defective myo-
blasts rescues MyoD activity and differentiation poten-
tial. Additionally, in vivo studies on the 
 
Rb
 
 promoter
demonstrate that p53 regulates the 
 
Rb
 
 gene expression
at transcriptional level through a p53-binding site.
Therefore, here we show that p53 regulates myoblast
differentiation by means of pRb without affecting its
cell cycle–related functions.
 
Key words: p53 • Rb • MyoD • differentiation • muscle
 
Introduction
 
The differentiation of skeletal myoblasts is characterized
by permanent withdrawal from the cell cycle, biochemical
and morphological maturation into mononucleated myo-
cytes, and fusion into multinucleated myotubes. This pro-
gram depends on the expression and activation of myo-
genic basic helix-loop-helix (bHLH) regulatory factors
belonging to the MyoD family (for review, see Weintraub
et al., 1991) and on their cooperation with the myocyte-
specific enhancer binding factors MEF2 (Melkentin and
Olson, 1996; Yun and Wold, 1996). The activity of myo-
genic bHLH factors is regulated by the interaction with
non–tissue-specific proteins. Members of the E2 family
were shown to be necessary for binding of the myogenic
bHLH factors to DNA, while this binding is inhibited by
the presence of “inhibitor of differentiation” factors (for
review, see Wright, 1992). Other non–tissue-specific pro-
 
teins contribute to the cell cycle withdrawal, as well as
to the transcription of differentiation-associated genes.
These proteins include members of the cyclin-dependent
kinase inhibitors, such as p21
 
Waf1/Cip1
 
, and cell-cycle regula-
tors, such as pRb. p21
 
Waf1/Cip1
 
 is thought to inhibit pRb
phosphorylation and thus to promote the cell cycle with-
drawal that precedes terminal differentiation. This activity
of p21
 
Waf1/Cip1
 
 was shown to be p53-independent (Halevy
et al., 1995; Parker et al., 1995). The product of the 
 
Rb
 
gene possesses two different, genetically dissociated func-
tions in the differentiation process (Sellers et al., 1998).
The hypophosphorylated form of pRb contributes to the
cell-cycle withdrawal by acting as a transcriptional repres-
sor of the E2F-regulated genes, relevant to the cell-cycle
progression (Schneider et al., 1994; Weinberg, 1995, and
references therein). In addition, pRb cooperates with
MyoD to promote the expression of late markers of differ-
entiation (Gu et al., 1993; Chen et al., 1996; Novitch et al.,
1996) through the activation of the transcriptionally com-
petent MEF2 factors (Novitch et al., 1999).
 
The product of the tumor suppressor gene 
 
TP53
 
 is a
prominent regulator of cell-cycle checkpoints and apop-
totic death. Furthermore, considerable experimental evi-
dence has accumulated suggesting that a fine regulation of
the p53 protein activity is required for optimal develop-
ment and differentiation (for reviews, see Almog and Rot-
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ter, 1997; Choi and Donehower, 1999). p53 expression
and/or activity increases during at least some differentia-
tive processes such as hematopoiesis (Kastan et al., 1991),
spermatogenesis (Almon et al., 1993), and myogenesis
(Halevy et al., 1995; Soddu et al., 1996; Tamir and Bengal,
1998). Exogenous p53 expression can induce differentia-
tion in a variety of tumor cells in vitro (reviewed in Almog
and Rotter, 1997) and in vivo (Bossi et al., 2000), while al-
terations of the 
 
TP53
 
 gene in vivo frequently correlate
with undifferentiated phenotypes of cancers (Feinstein et
al., 1991; reviewed in Fagin, 1995). By in situ hybridiza-
tion, it was observed that 
 
TP53
 
 mRNA is present at high
levels in all mouse embryonic cells from embryonic day
(E) 8.5 to E 10.5. At later stages of development, 
 
TP53
 
 ex-
pression becomes more pronounced during the differenti-
ation of specific tissues and declines in mature tissues
(Schmid et al., 1991). By using immortal and primary myo-
blasts and myeloblasts, we have previously demonstrated
that the expression of dnp53 proteins strongly reduces ter-
minal differentiation into myotubes and granulocytes/
monocytes. In contrast, dnp53 expression does not affect
the cell cycle withdrawal and the apoptotic death associ-
ated with these differentiation processes (Soddu et al.,
1996; Mazzaro et al., 1999). Comparable results were ob-
tained with MyoD-converted p53
 
2
 
/
 
2
 
 fibroblasts (Cerone
et al., 2000). Interference with p53 mRNA or protein was
shown to inhibit the development of 
 
Xenopus laevis
 
(Wallingford et al., 1997). Despite the normal viability of
the original 
 
TP53
 
 null mice (Donehower et al., 1992), it
has become increasingly evident that a fine balance of p53
expression and activation is required for the normal de-
velopment of total embryo or single organs (for review,
see Choi and Donehower, 1999). The complete absence of
p53 can result in reduced fertility and exencephaly in
some mouse strains (Armstrong et al., 1995; Sah et al.,
1995), or in mice receiving low folic acid concentration in
the diet (Choi and Donehower, 1999). Not less deleterious
is the overexpression or the aberrant activation of p53.
This was shown by the early embryonic lethality of 
 
TP53
 
transgenic or 
 
mdm2
 
 null mice, as well as by the rescue of
the latter phenotype through the double knock out of the
 
mdm2
 
 and 
 
TP53
 
 genes (Montes de Oca Luna et al., 1995).
All these observations strongly support the involvement
of the 
 
TP53
 
 gene in cell differentiation and development.
Nevertheless, the pathways modulated by p53 in these
processes are still unknown, as are the effectors of these
biological events.
To identify the molecules that are downstream of p53 in
differentiation, we took advantage of the C2C12 myoblast
model we previously employed to demonstrate that dnp53
expression interferes with terminal differentiation into
skeletal myotubes (Soddu et al., 1996). Moreover, critical
experiments were confirmed on p53
 
1
 
/
 
1
 
 and p53
 
2
 
/
 
2
 
 pri-
mary myoblasts. We compared the expression of myogen-
esis-regulated genes in parental and dnp53-expressing
C2C12 myoblasts, in differentiation promoting conditions.
The serial analysis of gene expression and the consequent
biochemical and functional studies showed that p53 regu-
lates, at the transcriptional level, the increased expression
of pRb, which is involved in the execution of the muscle
differentiation program together with MyoD. No modifi-
cation was found in the pRb-dependent cell-cycle with-
 
drawal, indicating that during myogenesis p53 specifically
acts on the differentiation functions of pRb.
 
Materials and Methods
 
Differentiation Assay
 
Mouse satellite cells (MSC)
 
1
 
 were explanted from new-born mice and
maintained in culture as described (Mazzaro et al., 1999). To avoid spon-
taneous differentiation, primary satellite and C2C12 cells were never al-
lowed to reach confluence. Muscle differentiation was induced by serum
withdrawal (DMEM plus 10 
 
m
 
g/ml insulin and 5 
 
m
 
g/ml transferrin, or plus
2% horse serum), as described (Soddu et al., 1996; Mazzaro et al., 1999).
Differentiation was evaluated by indirect immunofluorescence for myosin
heavy chain (MyHC) (Crescenzi et al., 1994). Differentiation index was
calculated by counting at least 400 nuclei per dish, and applying the fol-
lowing formula: differentiation index 
 
5
 
 number of nuclei in differentiated
cells/total number of nuclei.
 
Northern Blot Hybridization
 
Total cellular RNA was extracted by RNeasy Mini Kit (QIAGEN), fol-
lowing the manufacturer’s instructions. Aliquots of 20 
 
m
 
g per lane were
electrophoresed through 1.5% agarose gel in the presence of formalde-
hyde. Gels were blotted onto Duralose nitrocellulose membrane (Strat-
agene) and hybridized according to standard protocols (Ausbel et al.,
1987). Probes were gel-purified and labeled with [
 
32
 
P]-dCTP (Dupont) by
random primer extension (Ausbel et al., 1987).
 
Western Blotting
 
Cells were plated in 60-mm dishes (7.5 
 
3 
 
10
 
4
 
/dish) and incubated in
growth medium (GM) or in differentiation-promoting medium (DM)
for different times. Approximately 30 min before harvesting the cells,
Hoechst 33258 dye was added to the culture medium (GM or DM) to a fi-
nal concentration of 1 
 
m
 
g/ml, to stain nuclei. 20 different microscopic
fields for each sample were analyzed by fluorescent microscope to esti-
mate the total number of nuclei per dish. Equal numbers of nuclei were
lysed in hot Laemmli buffer, loaded on 7 or 10% SDS-polyacrylamide
gels, electrophoresed, and blotted onto nitrocellulose membranes (Bio-
Rad Laboratories). Filters were immunoreacted with anti–pRb G3-245
mAb (PharMingen), anti–MyHC MF-20 mAb (Bader et al., 1982), or
anti–Hsp70 N27F3-4 mAb (StressGen Biotechnologies). Immunoreactiv-
ity was determined using the ECL-chemiluminescence reaction (Amer-
sham Corp.) following the manufacturer’s instructions.
 
Plasmids, Viruses, and Cell Transduction
 
The following plasmids were used for transfections: pN53cG(Val135), car-
rying the temperature-sensitive p53Val
 
135
 
 mutant gene (Michalovitz et al.,
1990) and the neo gene; pRSVneo, carrying the selectable marker for G418
resistance; pLxSP, carrying the selectable marker for puromycin resistance;
pMCK-luc, carrying 1,256 base pairs of the muscle creatine kinase (MCK)
promoter upstream of the luciferase reporter gene (Novitch et al., 1999);
pXRP1 and pd92, carrying the luciferase reporter gene driven by the human
Rb promoter between 
 
2
 
686 and 
 
2
 
4 and between 
 
2
 
686 and 
 
2
 
92, respec-
tively, relative to the translation start site (Osifchin et al., 1994); and
pXRP1-mtp53, obtained from the pXRP1 vector by the QuikChange site-
directed mutagenesis kit (Stratagene). In the last vector, the sequence of the
p53 binding site (between 
 
2
 
82 and 
 
2
 
73) 5
 
9
 
-GGGCGTGCCC-3
 
9
 
 was mu-
tated in 5
 
9
 
-TGTCGTTAAC-3
 
9
 
, and the mutation was confirmed by direct
sequencing. C2C12 cells were transfected by CaPO
 
4
 
-mediated DNA precip-
itation by using a 1:20 molar ratio between resistance and experimental vec-
tors, when required. Selection was performed in the presence of 0.75 mg/ml
G418, or 2 
 
m
 
g/ml puromycin. dnp53 protein expression was assessed by indi-
rect immunofluorescence and Western blotting (Soddu et al., 1996). Inte-
gration of luciferase reporter vectors was assessed by direct PCR using two
primers complementary to the luciferase gene.
 
1
 
Abbreviations used in this paper:
 
 Act D, actinomycin D; DM, differentia-
tion-promoting medium; dnp53, dominant-negative p53; GM, growth me-
dium; MCK, muscle creatine kinase; MSC, mouse satellite cell; MyHC,
myosin heavy chain. 
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Recombinant adenoviruses Adp53 (Bacchetti and Graham, 1993), en-
coding a human wt-p53 protein and Ad-
 
D
 
Rb (Chang et al., 1995), encod-
ing a low phosphorylable human Rb protein, and the replication defective,
E1-deleted dl312 control adenovirus were prepared and titrated by 293-
cell infection. Recombinant retroviruses Ltsp53SN, encoding p53Val
 
135
 
mutant and the insertless LxSN, were produced by GP
 
1
 
E packaging cells.
 
Luciferase Activity
 
Luciferase activity was assessed as described (Osifchin et al., 1994) and
normalized as reported for Western blotting.
 
In Vivo Footprinting and
Chromatin Immunoprecipitation
 
For in vivo footprinting, proliferating and differentiated cells were treated
with 0.06% dimethyl sulfate (Sigma-Aldrich) for 30 s. DNA was extracted
and cleaved with piperidine (Sigma-Aldrich). As control, purified ge-
nomic DNA was methylated in vitro with 0.125% dimethyl sulfate for
2 min. In vivo footprintings were performed by legation-mediated
PCR (Martinez-Balbas et al., 1995) using the following primers: 5
 
9
 
-
CCCGACTCCCGTTACAAAAATAATG-3
 
9
 
 (56.33
 
8
 
C), 5
 
9
 
-GAACGTC-
CCCCGAGGAAAACCG-3
 
9
 
 (61.65
 
8
 
C), and 5
 
9
 
-AACGTCCCCCGAG-
GAAAACCGGACGC-3
 
9
 
 (65.8
 
8
 
C).
For chromatin cross-linked immunoprecipitation, proliferating and dif-
ferentiated cells were cross-linked by adding formaldehyde directly to cul-
ture medium. DNA preparation, immunoprecipitation, and amplification
were performed as described (Boyd et al., 1998). Affinity purified rabbit
or sheep polyclonal antibodies were employed: anti–Sp1 sc-59-X (Santa
Cruz Biotechnology, Inc.) and anti–p53 Ab-7 (Calbiochem). The follow-
ing primers were employed to amplify the indicated promoters: the
murine 
 
Rb
 
 promoter, 5
 
9
 
-GACGACGCGGGCGGAGACAGG-3
 
9
 
, 5
 
9
 
-
AACGTCCCCCGAGGAAAACCGGACGC-3
 
9
 
; the human 
 
Rb
 
 promoter
upstream the luciferase gene, 5
 
9
 
-GAGGGCGCGTCCGGTTTTTCTCA-
3
 
9
 
, 5
 
9
 
-AGCAATTGTTCCAGGAACCAGGGCATAGC-3
 
9
 
; the murine
 
MyoD
 
 promoter, 5
 
9
 
-CCTGGGGCTATTTATCCCCAGGGTAGCC-3
 
9
 
,
5
 
9
 
-TAGACCACTGGAGAGGCTTGGGCAG-3
 
9
 
; the murine myosine
light chain promoter, 5
 
9
 
-CTTCAGTCTCACCAGGGCTGTTCAC-3
 
9
 
, 5
 
9
 
-
CTCTCTCTGGCTTCCTTTTTATTTCTGGGC-3
 
9
 
, the murine desmin
promoter, 5
 
9
 
-TGCTTCCTAGCTGGGCCTTTCC-3
 
9
 
, 5
 
9
 
-CCGGACAG-
GTCTCTACCATCCTTTC-3
 
9
 
.
 
Results
 
Myoblasts from p53
 
2
 
/
 
2
 
 Mice Have Reduced 
Differentiation Capacity
 
We have previously demonstrated that the expression of
dnp53 proteins in primary and immortalized myoblasts in-
hibits their differentiation (Soddu et al., 1996; Mazzaro et
al., 1999). These dnp53 proteins should form mixed, tran-
scriptionally inactive oligomers with the endogenous wt-
p53 protein (Milner and Medcalf, 1991). Recently, some
weak but transcriptionally relevant heterotypic interac-
tions have been described between some mutant p53 and
p63 or p73 proteins (Davison et al., 1999; Di Como et al.,
1999), which are members of the newly discovered p53
family (for reviews, see Oren, 1997; Kaelin, 1999). Since
p63 and p73
 
 
 
knock-out mice present more evident devel-
opmental defects than p53
 
2
 
/
 
2
 
 mice (Mills et al., 1999;
Yang et al., 1999, 2000), it is possible that the inhibition of
myoblast differentiation induced by the dnp53 expression
is due to the inactivation of other p53 family members. We
have shown that MyoD-converted, p53
 
2
 
/
 
2
 
 fibroblasts have
a significant reduction in their differentiation capacity,
compared with the p53
 
1
 
/
 
1
 
 fibroblasts (Cerone et al., 2000).
Still, to more directly demonstrate a p53-specific role in
myogenesis, primary myoblasts were explanted from p53
 
1
 
/
 
1
 
and p53
 
2
 
/
 
2
 
 mice to study their differentiation capacity.
 
Time course analyses of differentiation showed a strong and
persistent reduction of differentiation indices in p53
 
2
 
/
 
2
 
,
compared with p53
 
1
 
/
 
1
 
 myoblasts (Fig. 1 a). This reduction
was completely rescued by the expression of an exogenous
wt-p53 protein obtained by myoblast infection with a p53-
carrying recombinant adenovirus (Bacchetti and Graham,
1993) (Fig. 1 b). These results demonstrate that the other
members of the p53 family cannot substitute the p53-spe-
cific role in muscle differentiation.
 
p53-defective Myoblasts Do Not Upregulate
Rb Expression
 
To identify the molecules downstream of p53 in the differ-
entiation process, we evaluated the expression of a series of
muscle differentiation–regulated genes in myoblasts de-
rived from the C2C12 cell line. Total RNA was extracted
from parental (C2C12) and dnp53-expressing (C2-dnp53)
myoblasts (Soddu et al., 1996) maintained in GM, or incu-
bated in the presence of DM for different times. As ex-
pected, C2-dnp53 cells had a strong reduction in the ex-
pression of muscle structural genes, like 
 
MyHC
 
, compared
with the parental cells (Fig. 2, a and b). A series of genes,
including 
 
MyoD
 
, 
 
myogenin
 
, 
 
p21
 
Waf1/Cip1
 
, 
 
cyclin D1
 
 and 
 
D3
 
,
and 
 
Id-1
 
, were found to behave similarly in the two cell
types (Fig. 2 a). In contrast, a strong difference in the 
 
Rb
 
mRNA induction was present between parental and C2-
dnp53 cells (Fig. 2, a and c), the latter being largely im-
paired in their ability to increase the 
 
Rb
 
 mRNA levels. This
difference was even more marked at the protein level (Fig.
2 d) and was confirmed in p53
 
2
 
/
 
2
 
 primary myoblasts (e).
Moreover, infection of the p53
 
2
 
/
 
2
 
 primary myoblasts with
recombinant retroviruses carrying the dnp53 protein did
not further inhibit MyHC and Rb expression (Fig. 2 e) and
differentiation indices (15.3 and 16.7% in neo and dnp53-
expressing cells, respectively), supporting the p53 specific-
ity for this differentiation activity. Interestingly, Rb expres-
sion in proliferating conditions was similar in parental and
p53-impaired cells, suggesting a specific p53 control on the
differentiation-associated upregulation of the 
 
Rb
 
 gene.
To evaluate whether the differentiation-associated 
 
Rb
 
upregulation was stably inhibited in the C2-dnp53 cells, or
Figure 1. Effects of p53 impairment on muscle differentiation.
(a) Time-course analysis of differentiation indices of mouse satel-
lite cells (MSC) explanted from p531/1 and p532/2 mice. (b)
p532/2 MSC were induced to express wt-p53 protein by infection
with the Adp53 recombinant adenovirus. The E1A-deleted dl312
adenovirus was used as negative control. Time course analysis of
differentiation indices was performed as in a. 
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this inhibition was dependent on the sustained expres-
sion of exogenous dnp53 protein, we took advantage of
this particular dnp53 protein being temperature sensitive
(Michalovitz et al., 1990). Northern blot analysis was per-
formed on parental and C2-dnp53 cells at the permissive
temperature (328C). The complete recovery of the differ-
entiation ability of C2-dnp53 cells at 328C (Soddu et al.,
1996) was associated with that of MyHC and Rb expres-
sion levels (Fig. 2 f). These results indicate that inhibitions
of differentiation and of Rb  upregulation are reversible
consequences of p53 inactivation.
p53 Does Not Interfere with the Cell Cycle-related 
Functions of pRb
Skeletal muscle cells belong to those cell types in which
differentiation is associated with irreversible withdrawal
from the cell cycle (Crescenzi et al., 1995). In differentiat-
ing conditions, Rb2/2 myoblasts are defective in cell cycle
withdrawal and expression of late markers of differentia-
tion (Schneider et al., 1994; Novitch et al., 1996). Further-
more, those Rb2/2 myoblasts that stop proliferating and
reach differentiation can re-enter the cell cycle after serum
stimulation (Schneider et al., 1994). Since C2-dnp53 cells,
which stop proliferating upon induction of differentiation
(Soddu et al., 1996), are drastically inhibited in their differ-
entiation capacity and do not upregulate Rb (as assessed
at the population level), we evaluated whether these cells
can re-enter the cell cycle upon serum stimulation. We
found that most of the MyHC-negative, undifferentiated
cells, which stop proliferating after serum starvation, reac-
tivated DNA synthesis as well as parental cells (80% in the
C2-dnp53 population and 70% in the parental one). By
contrast, MyHC-positive C2-dnp53 cells were not able to
Figure 2. Serial analysis of muscle differentiation–regulated gene expression. (a) Northern blot hybridizations were performed on total
RNA extracted from C2C12 and C2-dnp53 cells incubated in DM for the indicated times, or maintained in GM. (b and c) Quantitative
analyses, relative to GAPDH, of the gene expression levels observed in a were evaluated for MyHC and Rb in the indicated cells. (d)
C2C12 and C2-dnp53 cells, incubated as in a, were analyzed by Western blotting for the listed proteins. The numbers represent quanti-
tative data relative to Hsp70. (e) p531/1 and p532/2 MSC were incubated as in a. p532/2 MSC were also transduced with the indicated
gene by retroviral infection and incubated for 96 h in DM. Total cell lysates from each of these cell lines were analyzed by Western blot-
ting for the listed proteins. (f) C2C12 and C2-dnp53 cells were incubated in GM, or in DM for 96 h, and maintained at 328C. Northern
blot hybridization was performed for the indicated genes. The numbers represent quantitative data relative to GAPDH.Porrello et al. p53 Regulates Differentiation through pRb 1299
reactivate the cell cycle any longer. Indeed, we could
never find BrdUrd/MyHC double-positive cells in all the
experiments performed. In addition, the expression of
pRb protein was analyzed at the single-cell level by indi-
rect immunofluorescence. As shown in Fig. 3, the C2-
dnp53 cells that could differentiate had increased levels of
pRb. Moreover, the hypophosphorylation of pRb, which is
responsible for cell cycle withdrawal, was similarly present
in parental and dnp53-expressing cells (data not shown),
as well as in p531/1 and p532/2 myoblasts (Fig. 2 e). Taken
together, these results indicate that p53 is not essential for
the cell cycle–related functions of pRb.
p53 Controls the Differentiation Activity of pRb
A pRb function genetically distinct from cell cycle control
affects the transcription of differentiation-related genes
(Sellers et al., 1998; Novitch et al., 1999), pRb being re-
quired for the full function of the transcription factor
MyoD during skeletal muscle differentiation (Gu et al.,
1993; Novitch et al., 1996, 1999). Thus, MyoD transcrip-
tional activity was measured in C2C12 and C2-dnp53 cells
stably transfected with a reporter vector containing the
MCK promoter. Upon induction of differentiation, a con-
siderable accumulation of the luciferase reporter was
found in parental C2C12 cells, while a strongly reduced ac-
cumulation was detectable in C2-dnp53 cells. This reduc-
tion was fully suppressed by infection with a recombinant
adenovirus encoding an active pRb (Ad-DRb; Chang et
al., 1995) (Fig. 4 a). Since MyoD activity was rescued by
exogenous pRb overexpression, we evaluated the differen-
tiation capacity of these cells. As shown in Fig. 4 b, Ad-
DRb–infected C2-dnp53 cells differentiate as efficiently as
the parental C2C12 cells, indicating that exogenous pRb
overexpression is sufficient to recover the differentiation
capacity of C2C12 cells lacking p53 activity. Altogether,
these results strongly indicate that p53 controls the differ-
entiation function of pRb.
Differentiation-associated Rb Upregulation Is Mediated 
at the Transcriptional and Posttranscriptional Levels
It has been suggested that, during myoblast differentiation,
Rb mRNA upregulation is transcriptionally mediated (Mar-
telli et al., 1994; Okuyama et al., 1996). Thus, the luciferase
reporter vector pXRP1, which carries the 2686 to 24 base-
pair fragment of the human Rb promoter (Osifchin et al.,
1994), was stably transfected into C2C12 cells. The kinetics
of luciferase expression was evaluated in two different poly-
clonal populations upon induction of differentiation and
compared with the levels of proliferating cells (time 0). A
strong reduction in luciferase activity was present 24 h after
differentiation induction. This initial downregulation was
followed by the recovery of the promoter activity at the 48 h
time point (Fig. 5 a), with no considerable difference be-
tween the two populations analyzed (b). Interestingly, in all
the time courses performed, the differentiation-associated
luciferase activity never reached the level measured in pro-
liferating cells. This suggests the presence of a different type
of Rb gene transcription between the proliferating and dif-
ferentiating states. Thus, to detect possible differential occu-
pations of cis-acting elements in the two conditions, in vivo
footprintings were performed on the endogenous Rb pro-
moter of C2C12 cells. The Rb promoter region responsible
for the regulation during in vitro myogenesis (Okuyama et
al., 1996) was analyzed. Proliferating and 48 h-differentiated
cells showed different patterns of nucleotide protection (Fig.
5 c), supporting the idea of the presence of different tran-
scriptional complexes in the two conditions compared.
Figure 3. pRb expression in differentiated myotubes. (Top) Indi-
rect immunofluorescence performed on C2C12 and C2-dnp53
cells 72 h after the incubation in DM. Anti–pRB mAb was re-
vealed by TRITC-conjugated antiserum and anti–MyHC serum
by FITC-conjugated antiserum. (Bottom) Hoechst-stained nuclei
pictures superimposed on the relative phase contrast images of
the same fields shown above.
Figure 4. Effects of pRb overexpression in C2-dnp53 cells. (a)
Activity of the MCK promoter in the cells indicated. C2C12
cells were stably transfected with the MCK reporter vector and
subsequently infected with dnp53-carrying or insertless retro-
virus. The C2-MCK-dnp53 cells were also infected with Ad-DRb
virus to increase pRb expression or dl312 adenovirus as con-
trol. Fold induction values indicate the ratio between the val-
ues obtained in DM (48 h) and GM conditions. (b) Differenti-
ation indices were evaluated at the indicated time points in
C2C12 and C2-dnp53 cells before and after infection with ade-
novirus as in a.The Journal of Cell Biology, Volume 151, 2000 1300
Since the increment of Rb mRNA levels during C2C12
differentiation is not proportional to the increase in the
Rb promoter activity in the same conditions, we asked
whether posttranscriptional regulation of the Rb gene ex-
pression was also present. Northern blot analyses were
performed on total RNA extracted from C2C12 and C2-
dnp53 cells treated with the transcription inhibitor Actino-
mycin D (Act D). In proliferating conditions, reduction of
Rb mRNA levels was found in both cell types compared
with the relative untreated cells. At 48 h from differentia-
tion induction, comparable amounts of Rb mRNA were
present in cells treated and untreated with Act D, al-
though, as expected, the absolute levels were different be-
tween parental and C2-dnp53 cells (Fig. 5 d).
Altogether, the results reported in this paragraph demon-
strate that the differentiation-associated Rb upregulation is
mediated at the transcriptional and posttranscriptional lev-
els and that the latter type of control is p53 independent.
During Muscle Differentiation, p53 Contributes to the 
Transcriptional Regulation of the Rb Promoter through 
a p53-binding Site
Since the p53 transcriptional activity is required for the in-
duction of differentiation (Soddu et al., 1996), we evaluated
whether p53 contributes to the Rb gene transcription.
pXRP1-carrying C2C12 cells were stably transduced with
the dnp53 protein by retroviral infection and maintained as
polyclonal populations. When these cells were incubated in
DM, the Rb promoter showed the 24 h silencing that, how-
ever, was not followed by the normal 48 h recovery of tran-
scriptional activity (Fig. 6 a). This finding indicates that p53
contributes to the increase of the Rb promoter activity that
occurs during C2C12 differentiation after the initial silenc-
ing. The timing of this recovered activity correlates with
the p53-specific transcriptional activity that we previously
measured on the artificial p53-reporter vector PG13-CAT
(Soddu et al., 1996). Notably, no difference in Rb promoter
activity was found between parental and dnp53-expressing
C2C12 cells in proliferating conditions, as assessed by stable
and transient transfections of C2C12 and C2-dnp53 cells
with the pXRP1 (data not shown). These results further
support the idea that p53 is involved only in the differentia-
tion-associated upregulation of the Rb gene.
Since a sequence positively regulated by p53 had been
mapped in the Rb promoter between 292 and 24 base-
pairs upstream of the translation start site (Osifchin et al.,
1994), we stably transfected into C2C12 cells a pXRP1 vec-
tor carrying a deletion of this region (pd92) (Osifchin et al.,
1994). As shown in Fig. 6 b, after the expected promoter si-
lencing at 24 h, no activation of pd92 transcription was
present at 48 h, supporting the hypothesis that during
C2C12 differentiation p53 modulates the Rb promoter
through the p53-binding site present in this region. To con-
firm this hypothesis, the p53-binding site was mutated in the
pXRP1 vector, creating the pXRP1-mtp53 that was stably
transduced into C2C12 cells. Upon differentiation induc-
tion, the levels of luciferase activity of pd92 and pXRP1-
mtp53 were comparable (Fig. 6 b), indicating that p53 regu-
lates Rb transcription through this p53-binding site.
Because of the particularly high content in Guanine–
Cytosine of the Rb promoter region containing the p53-bind-
ing site, we were not able to perform in vivo footprintings
of this site. Thus, to verify the in vivo p53 binding to the
Figure 5. Rb promoter activity in muscle differentiation. (a) pRXP1-carrying C2C12 cells (C2-P1) were incubated in DM for different
times. Time 0 indicates cells maintained in GM. Luciferase activity was normalized for number of nuclei. (b) Two different polyclonal
populations of pRXP1-carrying C2C12 cells (C2-P1 Mix1 and C2-P1 Mix2) were incubated as in a. Columns report the luciferase activ-
ity of each cell line, relative to its own GM. (c) The region between 2219 and 2143 base-pairs upstream of the translation start site of
the C2C12 endogenous Rb promoter was analyzed by in vivo footprinting in proliferating (P) and 48 h differentiated (D) cells; in vitro
footprinting (V) was used as control. (Continuous arrows) Bands that are significantly protected; (dashed arrows) bands that are not
protected; and (*) spurious bands. (d) Total RNA was extracted from C2C12 and C2-dnp53 cells maintained in GM or DM for 48 h,
with or without Act D. Northern blottings were performed for the Rb and GAPDH genes. Histograms show quantitative analyses of the
Rb gene expression levels relative to GAPDH.Porrello et al. p53 Regulates Differentiation through pRb 1301
proximal region of the Rb promoter, a chromatin–cross-
linked immunoprecipitation was performed (Boyd et al.,
1998) in C2C12 cells maintained in the presence of GM or
DM and in p531/1 and p532/2 MSC incubated in DM. Pro-
teins were cross-linked to DNA by direct incubation of liv-
ing cells with formaldehyde. DNA was extracted, immuno-
precipitated with anti–p53 or anti–SP1 sera, and the Rb
promoter sequence was amplified from the immunoprecip-
itate by PCR. We found the proximal region of the Rb pro-
moter in the p53-bound cross-linked chromatin of C2C12
and p531/1 MSC (Fig. 6 c), indicating the presence of p53 in
the complexes that bind the Rb promoter in vivo. The Rb
promoter sequence could not be amplified from the anti–
p53 immunoprecipitated chromatin obtained from p532/2
MSC, demonstrating the specificity of the anti–p53 immu-
noprecipitation. In the same experiment, the E2F promoter
that contains the SP1-binding site, but not the p53-binding
site, was used as control. To further confirm p53 binding to
the Rb promoter, the C2-P1 cells carrying the exogenous
human Rb promoter were in vivo cross-linked. The se-
quence of exogenous human and endogenous murine Rb
promoters, as well as a series of muscle specific promoters
that do not contain p53-binding sites were amplified from
the same DNA immunoprecipitations (Wells et al., 2000).
As shown in Fig. 6 d, both human and mouse Rb promoters
could be amplified, while no amplification was detectable
in the control promoters. These results support the conclu-
sion that p53 binds the Rb promoter in muscle cells.
Discussion
The TP53 gene has been largely characterized as a cell-cycle
checkpoint controller and an apoptosis inducer. In addition,
different studies performed in vivo and in vitro have indi-
cated a p53 involvement in embryonic development and
in cell differentiation. However, the mechanisms through
which p53 influences differentiation and development are
substantially unknown. In the present report, we show that,
during skeletal muscle differentiation, p53 is required to es-
tablish the increased level of pRb expression, which regu-
lates the further steps of muscle differentiation (Fig. 7).
The pRb requirement in skeletal muscle differentiation
has been extensively studied. Inactivation of the pRb func-
tion by proteins from DNA-tumor viruses, as well as stud-
ies performed with Rb2/2 cells have shown that pRb is in-
volved in cell-cycle withdrawal and in the expression of late
markers of differentiation (Gu et al., 1993; Chen et al.,
1996; Novich et al., 1996, 1999). These two pRb functions
can be genetically and mechanistically dissociated, as it has
been elegantly demonstrated by studying pRb mutants
from high- and low-risk retinoblastomas (Sellers et al.,
1998). pRb can inhibit DNA synthesis thanks to its ability
to bind E2F and DNA, and to repress transcription through
a specific domain. In contrast, the abilities to activate tran-
scription and promote differentiation do not require E2F
binding, but rather need cooperation with other types of
transcription factors, such as MyoD. We found that, in
the presence of differentiation-promoting stimuli, p53-
impaired myoblasts maintain the capacity to hypophos-
phorylate pRb and to withdraw from the cell cycle, while
losing their capacity to increase pRb expression and have
strongly reduced MyoD activity and differentiation poten-
tial. These findings indicate that p53 discriminates between
the cell cycle– and differentiation-related functions of pRb
and provide a biological counterpart to the biochemical char-
acterization of the pRb mutants described above (Sellers et
al., 1998). Furthermore, our results are in good agreement
with the observations indicating that the pRb hypophos-
phorylation responsible for the differentiation-associated cell
cycle withdrawal involves a p53-independent p21Waf1/Cip1 up-
regulation (Halevy et al., 1995; Parker et al., 1995).
In physiological proliferating conditions, our p53-
impaired myoblasts did not show any modification of the
Rb gene expression, as shown by Northern and Western blot,
Figure 6. p53 activity on the Rb promoter. (a) C2-P1 cells were infected with a recombinant retrovirus carrying the dnp53 gene or its in-
sertless control. Relative luciferase activity was assessed on polyclonal populations as described in Fig. 5. (b) C2C12 cells were stably trans-
duced with pXRP1 (C2-P1), pd92 (C2-d92), and pXRP1-mtp53 (C2-P1mtp53). Relative luciferase activity was assessed on polyclonal pop-
ulations as in a. (c and d) Cross-linked chromatin from the indicated cells was immunoprecipitated with antibodies to p53, Sp1, or in the
absence of antibodies, and analyzed by PCR with primers specific for the indicated promoters (see Materials and Methods). Sp1 was used
as positive control in the promoters with an SP1-binding site; input corresponds to nonimmunoprecipitated cross-linked chromatin.The Journal of Cell Biology, Volume 151, 2000 1302
and by promoter activation analyses. These observations
are consistent with the notion that p53 is not involved in
cell cycle control in normal proliferating conditions. In
contrast, it is well known that different types of stressing
stimuli promote p53 activation. In this type of situation,
p53 is known to promote pRb hypophosphorylation and
inhibition of DNA synthesis through the transcriptional
induction of p21Waf1/Cip1 (Dulic et al., 1994). Indeed, com-
pared with the parental cells, C2-dnp53 cells do not arrest
in the G1 phase of the cell cycle in response to doxorubi-
cin-induced DNA damage (Manni et al., manuscript sub-
mitted for publication). Together with the findings we ob-
tained in differentiating conditions, these results indicate
the presence of two different types of p53-dependent regu-
lation of pRb. One operates through p21Waf1/Cip1 transcrip-
tion, and the other through direct Rb transcription. These
observations are consistent with the emerging idea that
p53 regulates transcription of different genes, depending
on the type of stimuli that provoked its activation (Zhao et
al., 2000). Interestingly, the existence of a positively regu-
lated p53-binding site on the Rb promoter has been known
for several years (Osifchin et al., 1994), but no transcrip-
tional induction of the Rb gene was found in apoptotic or
growth-arresting situations, so far. Our results reveal the
existence of a physiological condition in which p53 directly
transactivates the Rb gene.
Recently, a family of p53-related proteins has been dis-
covered. This family includes, besides p53, p73 and p63
proteins that share homology with the activation, the
DNA-binding, and the oligomerization domains of p53.
These proteins, when overexpressed in mammalian cells,
can transactivate some of the p53 target genes and appear
to be involved in differentiation and development path-
ways (Oren, 1997; Kaelin, 1999; Mills et al., 1999; Yang et
al., 1999, 2000). The genetic analysis we performed by
comparing the differentiation abilities of primary myo-
blasts explanted from p531/1 and p532/2 mice allowed us
to distinguish the function of p53 from those of its family
members, demonstrating that the role played by p53 in
muscle differentiation is specific of this protein. This result
suggests that p53 and its family members have no overlap-
ping activities on differentiation and thus might not be
functionally redundant during ontogenesis. These consid-
erations leave open the discrepancy between impaired dif-
ferentiation of p53 null muscle cells in vitro and the ap-
parently normal muscle development in p53 null mice.
Temporary, slight defects in muscle development cannot
be ruled out since, to our knowledge, detailed develop-
mental analyses of skeletal muscles have not yet been per-
formed in p532/2 mice. On the other hand, an explanation
for this discrepancy might be suggested by the observation
that, in dnp53-expressing C2C12 cells, the inhibition of dif-
ferentiation is present only when these cells are stimulated
to differentiate by growth factor withdrawal (Soddu et al.,
1996) (Fig. 7). It is known that skeletal muscle differentia-
tion in vitro can be obtained by two different stimuli,
growth factor deprivation and cell to cell contact (Martelli
et al., 1994). We have found that cell confluence, even in
the presence of serum, is able to increase pRb expression
in a p53-independent manner (Coen, S., and S. Soddu, un-
published results). Differentiation-promoting stimuli due
to cell to cell contact can be avoided in vitro, but not dur-
ing in vivo development, suggesting that they can provide
a functional replacement for p53. We do not know the mo-
lecular mediators of this effect nor whether it is relevant
for development; nevertheless, the strong and frequent as-
sociation between p53 alterations and the undifferentiated
phenotypes described in many human cancers (Feinstein
et al., 1991; Fagin, 1995) is in agreement with this hypothe-
sis. Indeed, one peculiar characteristic of tumor transfor-
mation is the loss of contact inhibition. This would make
tumor cells more sensitive than their normal counterparts
to the absence of p53 in terms of differentiation capacity.
If proved, this hypothesis might solve an apparent incon-
gruity that has appeared between clinical and basic biolog-
ical researches in the p53 field. While basic research has
mostly studied the control of cell-cycle checkpoints and
the apoptotic function of p53, a large number of clinical
and epidemiological works have associatedTP53 gene al-
terations to loss of tumor differentiation (anaplasia). A
commonly accepted model has it that genomic instability
is the cause of anaplasia, through direct alterations of reg-
ulatory and structural differentiation genes. However, this
hypothesis is in contrast with the differentiation-promot-
ing effects of different compounds or of the exogenous ex-
pression of the wild-type p53 protein per se. Indeed, both
approaches induce differentiation in tumor cells without
correcting the genomic instability, suggesting a dual role
for p53 in tumor development as gatekeeper (Levine,
1997) and differentiation controller. The finding that
p53 regulates not only the cell-cycle progression function
of pRb, but also its differentiation-promoting function,
matches the TP53 gene to the prototypic oncosuppressors,
which are essential for embryonic development and play
important roles in regulating cell cycle and differentiation.
Figure 7. A model to explain p53 role in the induction of skeletal
muscle differentiation. Early steps of differentiation include the ac-
tivation of p21Waf1/Cip1 and the hypophosphorylation of pRb, which
leads to the transcriptional repression of the E2F-activated genes.
Findings (Halevy et al., 1995; Parker et al., 1995; Soddu et al., 1996;
this report) indicate that these steps are p53 independent. After the
cell-cycle withdrawal, p53 modifies the Rb gene transcription and
contributes to the increase of pRb expression levels. Therefore, the
upregulated pRb can cooperate with MyoD to transcribe later
markers of differentiation. Cell-to-cell contacts can also increase
pRb expression, overcoming the p53 requirement (Coen, S., and S.
Soddu, unpublished results). Further and later functions of p53,
such as the direct transcription of MCK promoter (Tamir and Ben-
gal, 1998) are not included in this model since they are related to
the activation of structural rather than regulatory genes.Porrello et al. p53 Regulates Differentiation through pRb 1303
We are particularly grateful to P.D. Robbins and M. Oren for generous
gifts of Rb promoter vectors and p53-recombinant retroviruses, to C. Co-
lussi for handling the p532/2 mice, to G. Bossi for primary cell preparation,
and to M. Crescenzi for constructive criticisms and helpful discussion.
This work was supported by Telethon-Italy and Associazione Italiana
per la Ricerca sul Cancro. A. Gurtner is the recipient of a fellowship from
Fondazione Italiana per la Ricerca sul Cancro.
Submitted: 31 May 2000
Revised: 16 October 2000
Accepted: 17 October 2000
References
Almog, N., and V. Rotter. 1997. Involvement of p53 in cell differentiation and
development. Biochim. Biophys. Acta. 1333:F1–F27.
Almon, E., N. Goldfinger, A. Kapon, N. Schwarts, A.J. Levine, and V. Rotter.
1993. Testicular tissue-specific expression of the p53 suppressor gene. Dev.
Biol. 156:107–116.
Armstrong, J.F., M.H. Kaufman, D.J. Harrison, and A.R. Clarke. 1995. High-
frequency developmental abnormalities in p53-deficient mice. Curr. Biol.
5:931–936.
Ausbel, F.M., R. Brent, R.E. Kinston, D.D. Moore, J.G. Seidman, J.A. Smith,
and K. Struhl. 1987. Current Protocols in Molecular Biology. Volume 1.
Wiley Interscience, New York, NY. 3.5.9 and 4.9.1–4.9.7
Bacchetti, S., and F. Graham. 1993. Inhibition of cell proliferation by an ade-
novirus vector expressing the human wild type p53 protein. Int. J. Oncol.
3:781–788.
Bader, D., T. Masaki, and D.A. Fischman. 1982. Immunochemical analyses of
myosin heavy chain during avian myogenesis in vivo and in vitro. J. Cell Biol.
95:763–770.
Bossi, G., R. Scardigli, P. Musiani, R. Martinelli, M.P. Gentileschi, S. Soddu,
and A. Sacchi. 2000. Development of a murine orthotopic model of leuke-
mia: evaluation of TP53 gene therapy efficacy. Cancer Gene Ther. 7:135–143.
Boyd, K.E., J. Wells, J. Gutman, S.M. Bartley, and P.J. Farnham. 1998. c-Myc
target gene specificity is determined by a post-DNA-binding mechanism.
Proc. Natl. Acad. Sci. USA. 95:13887–13892.
Cerone, M.A., A. Marchetti, G. Bossi, G. Blandino, A. Sacchi, and S. Soddu.
2000. p53 is involved in the differentiation but not in the differentiation-
associated apoptosis of myoblasts. Cell Death Diff. 7:506–508.
Chang, M.W., E. Barr, J. Seltzer, Y.Q. Jiang, G.J. Nabel, M.S. Parmacek, and
J.M. Leiden. 1995. Cytostatic gene therapy for vascular proliferative disor-
ders with a constitutively active form of the retinoblastoma gene product.
Science. 27:518–522.
Chen, P.L., D.J. Riley, S. Chen-Kiang, and W.-H. Lee. 1996. Retinoblastoma
protein directly interacts with and activates the transcription factor NF-IL6.
Proc. Natl. Acad. Sci. USA. 93:465–469.
Choi, J., and L.A. Donehower. 1999. p53 in embryonic development: maintain-
ing a fine balance. Cell. Mol. Life Sci. 55:38–47.
Crescenzi, M., D.H. Crouch, and F. Tatò. 1994. Transformation by myc pre-
vents fusion but not biochemical differentiation of C2C12 myoblasts: mecha-
nisms of phenotypic correction in mixed culture with normal cells. J. Cell
Biol. 125:1137–1145.
Crescenzi, M., S. Soddu, and F. Tatò. 1995. Cell cycle reactivation in terminally
differentiated cells by adenovirus infection. J. Cell Physiol. 162:26–35.
Davison, T.S., C. Vagner, M. Kaghad, A. Ayed, D. Caput, and C.H. Arrow-
smith. 1999. p73 and p63 are homotetramers capable of weak heterotypic in-
teractions with each other but not with p53. J. Biol. Chem. 274:18709–18714.
Di Como, C.J., C. Gaiddon, and C. Prives. 1999. p73 function is inhibited by tu-
mor-derived p53 mutants in mammalian cells. Mol. Cell Biol. 19:1438–1449.
Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery,
Jr., J.S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmen-
tally normal but susceptible to spontaneous tumors. Nature. 356:215–221.
Dulic, V., W.K. Kaufmann, S.J. Wilson, T.D. Tlsty, E. Lees, J.W. Harper, S.J.
Elledge, and S.I. Reed. 1994. p53 dependent inhibition of cyclin-dependent
kinase activities in human fibroblasts during radiation-induced G1 arrest.
Cell. 76:1013–1023.
Fagin, J.A. 1995. Tumor suppressor genes in human thyroid neoplasms: p53
mutations are associated with undifferentiated thyroid cancers. J. Endo-
crinol. Invest. 18:140–142.
Feinstein, E., R.P. Gale, J. Reed, and E. Canaani. 1991. p53 in chronic myeloge-
nous leukemia in acute phase. Proc. Natl. Acad. Sci. USA. 88:6293–6297.
Gu, W., J.W. Schneider, G. Condorelli, S. Kaushal, V. Mahdavi, and B. Nadal-
Ginard. 1993. Interaction of myogenic factors and the retinoblastoma pro-
tein mediates muscle cell commitment and differentiation. Cell. 72:309–324.
Halevy, O., B.G. Novitch, D.B. Spicer, S.X. Skapek, J. Rhee, G.J. Hannon, D.
Beach, and A.B. Lassar. 1995. Correlation of terminal cell cycle arrest of
skeletal muscle with induction of p21 by MyoD. Science. 267:1018–1021.
Kastan, M.B., A.I. Radin, S.J. Kuerbitz, O. Onyekwere, C.A. Wolkow, C.
Civin, K.D. Stone, T. Woo, Y. Ravindranath, and R.W. Craig. 1991. Levels
of p53 protein increase with maturation in human hematopoietic cells. Can-
cer Res. 51:4279–4286.
Kaelin, W.J., Jr. 1999. The emerging p53 gene family. J. Nat. Cancer Inst. 91:
594–598.
Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88:
323–331.
Martelli, F., C. Cenciarelli, G. Sartorelli, B. Polikar, A. Felsani, and M. Caruso.
1994. MyoD induces retinoblastoma gene expression during myogenic dif-
ferentiation. Oncogene. 9:3579–3590.
Martinez-Balbas, M.A., A. Dey, S. Rabindran, K. Ozato, and C. Wu. 1995. Dis-
placement of sequence-specific transcription factors from mitotic chromatin.
Cell. 83:29–38.
Mazzaro, G., G. Bossi, S. Coen, A. Sacchi, and S. Soddu. 1999. The role of wild-
type p53 in the differentiation of primary hemopoietic and muscle cells. On-
cogene. 18:5831–5835.
Melkentin, J.D., and E.N. Olson. 1996. Defining the regulatory networks for
muscle development. Curr. Opin. Genet. Dev. 6:445–453.
Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of trans-
formation and of cell proliferation by a temperature-sensitive mutant of p53.
Cell. 62:671–680.
Mills, A.A., B. Zheng, X.-J. Wang, H. Vogel, D.R. Roop, and A. Bradley. 1999.
p63 is a p53 homologue required for limb and epidermal morphogenesis. Na-
ture. 398:708–713.
Milner, J., and E.A. Medcalf. 1991. Cotranslation of activated mutant p53 with
wild type drives the wild-type p53 protein into the mutant conformation.
Cell. 65:765–774.
Montes de Oca Luna, R., D.S. Wagner, and G. Lozano. 1995. Rescue of early
embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 378:
203–206.
Novitch, B.G., G.J. Mulligan, T. Jacks, and A.B. Lassar. 1996. Skeletal muscle
cells lacking the retinoblastoma protein display defects in muscle gene ex-
pression and accumulate in S and G2 phases of the cell cycle. J. Cell Biol.
135:441–456.
Novitch, B.G., D.B. Spicer, P.S. Kim, W.L. Cheung, and A.B. Lassar. 1999. pRb
is required for MEF2-dependent gene expression as well as cell-cycle arrest
during skeletal muscle differentiation. Curr. Biol. 9:449–459.
Okuyama, Y., Y. Sowa, T. Fujita, T. Mizumo, H. Nomura, T. Nikaido, T. Endo,
and T. Sakai. 1996. ATF site of human RB gene promoter is a responsive el-
ement of myogenic differentiation. FEBS Lett. 397:219–224.
Oren, M. 1997. Lonely no more: p53 finds its kin in a tumor suppressor haven.
Cell. 90:829–832.
Osifchin, N.E., D. Jiang, N. Ohtani-Fujita, T. Fujita, M. Carrozza, S.-J. Kim, T. Sa-
kai, and P.D. Robbins. 1994. Identification of a p53 binding site in the human re-
tinoblastoma susceptibility gene promoter. J. Biol. Chem. 269:6383–6389.
Parker, S.B., G. Eichele, P. Zhang, A. Rawls, A.T. Sands, A. Bradley, E.N. Olson,
J.W. Harper, and S.J. Elledge. 1995. p53-independent expression of p21Cip1 in
muscle and other terminally differentiating cells. Science. 267:1024–1027.
Sah, V.P., L.D. Attardi, G.J. Mulligan, B.O. Williams, R.T. Bronson, and T.
Jacks. 1995. A subset of p53-deficient embryos exhibits exencephaly. Nat.
Genet. 10:175–180.
Schmid, P., A. Lorenz, H. Hameister, and M. Montenarh. 1991. Expression of
p53 during mouse embryogenesis. Development (Camb.). 113:857–865.
Schneider, J.W., W. Gu, L. Zhu, V. Mahdavi, and B. Nadal-Ginard. 1994. Re-
versal of terminal differentiation mediated by p107 in Rb2/2 muscle cells.
Science. 264:1467–1471.
Sellers, W.K., B.G. Novitch, S. Miyake, A. Heith, G.A. Otterson, F.J. Kaje,
A.B. Lassar, and W.J. Kaelin, Jr. 1998. Stable binding of E2F is not required
for the retinoblastoma protein to activate transcription, promote differentia-
tion, and suppress tumor cell growth. Genes Dev. 12:95–106.
Soddu, S., G. Blandino, R. Scardigli, S. Coen, A. Marchetti, M.G. Rizzo, G. Bossi,
L. Cimino, M. Crescenzi, and A. Sacchi. 1996. Interference with p53 protein in-
hibits hemopoietic and muscle differentiation. J. Cell Biol. 134:193–204.
Tamir, Y., and E. Bengal. 1998. p53 protein is activated during muscle differen-
tiation and participates with MyoD in the transcription of muscle creatine ki-
nase gene. Oncogene. 17:347–356.
Wallingford, J.B., D.W. Seufert, V.C. Virta, and P.D. Vize. 1997. p53 activity is
essential for normal development in Xenopus. Curr. Biol. 7:747–757.
Weinberg, R.A. 1995. The retinoblastoma protein and the cell cycle control.
Cell. 81:323–330.
Weintraub, H., R. Davis, S. Tapscott, M. Thayer, M. Krause, R. Benezra, K.T.
Blackwell, D. Turner, R. Rupp, S. Hollenberg, et al. 1991. The MyoD gene
family: nodal point during specification of the muscle cell lineage. Science.
251:761–766.
Wells, J., K.E. Boyd, C.J. Fry, S.M. Bartley, and P.J. Farnham. 2000. Target
gene specificity of E2F and pocket protein family members in living cells.
Mol. Cell. Biol. 20:5797–5807.
Wright, W.E. 1992. Muscle basic helix-loop-helix proteins and the regulation of
myogenesis. Curr. Opin. Genet. Dev. 2:243–248.
Yang, A., R. Schweitzer, D. Sun, M. Kaghad, N. Walker, R.T. Bronson, C.
Tabin, A. Sharpe, D. Caput, C. Crum, and F. McKeon. 1999. p63 is essential
for regenerative proliferation in limb, craniofacial and epithelial develop-
ment. Nature. 398:714–718.
Yang, A., N. Walker, R. Bronson, M. Kaghad, M. Oosterwegel, J. Bonnin, C.
Vagner, H. Bonnet, P. Dikkes, A. Sharpe, et al. 2000. p73-deficient mice
have neurological, pheromonal and inflammatory defects but lack spontane-
ous tumors. Nature. 404:99–103.
Yun, K., and B. Wold. 1996. Skeletal muscle determination and differentiation:
story of a core regulatory network and its context. Curr. Opin. Cell Biol.
8:877–889.
Zhao, R., K. Gish, M. Murphy, Y. Yin, D. Notterman, W.H. Hoffman, E. Tom,
D.H. Mack, and A.J. Levine. 2000. Analysis of p53-regulated gene expres-
sion patterns using oligonucleotide arrays. Genes Dev. 14:981–993